In this issue:
Risk of marrow neoplasms after adjuvant breast cancer therapy
Adding ovarian suppression in premenopausal breast cancer
Paclitaxel/trastuzumab in small, HER2+, node-negative tumours
Survival advantages with early palliative care intervention
Inappropriate medication use among older oncology patients
Ethnic differences in adjuvant breast cancer treatment . . . and adherence to adjuvant
endocrine therapy
5 years of tamoxifen for prevention: long-term effectiveness
Effects of a radiation boost after whole-breast irradiation
Healthy lifestyle and postmenopausal breast cancer risk
Please login below to download this issue (PDF)